(Q40582346)

21 September 2017

title

High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21). (English)

1 reference

21 September 2017

1 reference

acute myeloid leukemia

1 reference

Salvatore Palmieri

1

1 reference

21 September 2017

Lucia Sebastio

2

1 reference

21 September 2017

Giuseppina Mele

3

1 reference

21 September 2017

Mario Annunziata

4

1 reference

21 September 2017

Silvana Annunziata

5

1 reference

21 September 2017

Carolina Copia

6

1 reference

21 September 2017

Assunta Viola

7

1 reference

21 September 2017

Mariacarla De Simone

8

1 reference

21 September 2017

Barbara Pocali

9

1 reference

21 September 2017

Ettore Mariano Schiavone

10

1 reference

21 September 2017

Felicetto Ferrara

11

1 reference

21 September 2017

publication date

1 June 2002

1 reference

21 September 2017

1 reference

21 September 2017

volume

26

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

539-543

1 reference

Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Immunophenotypic analysis enables the correct prediction of t(8;21) in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Early blastic transformation of a myeloproliferative disorder with t(8;21) and progressive aberrations of chromosome 8

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900177-1

7 January 2021

10.1016/S0145-2126(01)00177-1

Identifiers

DOI

1 reference

release_lbws3ecu75fetitkfelgjhgtoa

21 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lbws3ecu75fetitkfelgjhgtoa

24 November 2022

mapped directly with Wikidata item

1 reference